about
Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process2012 revised International Chapel Hill Consensus Conference Nomenclature of VasculitidesDamage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.Missing laboratory test data in electronic general practice records: analysis of rheumatoid factor recording in the clinical practice research datalink.Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).Diagnosis and management of ANCA associated vasculitis.Introduction to, and classification of, the systemic vasculitides.Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisalHealth-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitisProgress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.Current status of outcome measure development in vasculitis.The phenotype of circulating follicular-helper T cells in patients with rheumatoid arthritis defines CD200 as a potential therapeutic target.The role of biologic therapies in the management of systemic vasculitis.Yersinia arthritis with erythema nodosum.The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.EULAR recommendations for the management of large vessel vasculitis.EULAR recommendations for the management of primary small and medium vessel vasculitis.Autoimmune markers for the diagnosis of rheumatoid arthritis in primary care: primary care diagnostic technology update.The RUDY study platform - a novel approach to patient driven research in rare musculoskeletal diseasesPharmacotherapy of vasculitis.Cardiovascular involvement in primary systemic vasculitis.An approach to the diagnosis and management of systemic vasculitis.Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.Damage assessment in ANCA-associated vasculitis.Vasculitis: an update.State of the art in the treatment of systemic vasculitides.Disease assessment in systemic vasculitis.Time to focus on outcome assessment tools for childhood vasculitis.The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study.Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study.The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.Explaining fatigue in ANCA-associated vasculitis.Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS).
P50
Q26795465-FA371408-AC7A-42B8-9A6E-3C8D89566DF4Q28276589-2B6E0F86-FE10-4B34-9CFD-1F4FFBE019C0Q30696868-0C1929C9-1B41-4F92-B6FA-7BCACBA5408EQ30849537-1004FB70-27A5-4430-9323-530723403FF2Q30908394-D5CB63FE-4BFA-4860-B368-3B2E5B563CC3Q30993164-A4B97E00-09CD-4C51-BD2A-7B8F6561F2C7Q34247611-653A12BC-AFCC-485D-B68C-8EBDF9B54AF2Q34317517-617D0DE7-366E-4079-96CC-3F4490E020DAQ34573847-D5D2888D-9204-4685-9F5F-4B253EFF6793Q35082362-AE95288E-390F-485B-A734-FE0858C585C4Q35114049-8657FFD2-D3E1-4F89-A6A0-16270B8BECA3Q35124613-40834E1E-5A8C-4AF9-83DA-F4BC8F21148EQ35579503-AC77504F-653C-4858-A228-499A88D50090Q35819013-AD6F4DDA-DD2A-496D-8F35-821F526C09DDQ35865798-012C8536-845D-4EF7-AB11-F07A28A7D3EDQ36317934-BB552876-5CA2-476F-93F7-02EF96BB9E61Q36477571-7C512AA0-6119-4839-B06A-C5B81CEC49D5Q36707125-FFA8A342-BDA5-4BD8-BC99-6006BEA1C65EQ36820858-3D7E9D7E-FC4E-45CB-92B3-121219551FD1Q36843077-B33EC240-C90E-4B04-BE46-DA7215DF4CC9Q37138796-E99CFDAC-94C0-4C69-A855-C192E8BEB7EBQ37138800-3F2E4C21-C97B-46D6-B7FE-3C98E8C9E07FQ37196816-298C3FB2-E32F-4BCA-B19F-8FDEE5591ECAQ37402943-5534CB0C-ED6A-4859-9903-B62194BA9165Q37483910-3A4479ED-770E-4F1A-B1B7-DAAB60C9EA8CQ37512800-5A310832-0BC4-4324-A98A-69019C9BEE49Q37673239-4B2444D5-E5CA-4ADC-8781-4FBD3BCAC269Q37879814-A99A554D-2B8F-47A1-8BBB-2B7C40FAD14DQ37926278-4F6F28F8-2DC9-41BD-8963-876DDA5007F9Q38043946-1509F22C-18CA-46DE-98A3-06762A62DE0AQ38238796-7B5002BE-7BBF-4F55-B93F-42636B8CE3CBQ38263514-AD524656-23C2-4B4A-A3D7-545CD188F3DDQ38348251-D2508DFE-406D-402D-BDE5-A169C636216BQ38695974-CA4F26B7-746D-4DD2-B62D-86BF81912579Q38786203-CFA0E22F-867E-4153-AE9D-8380E0586544Q39257920-FF7B501B-D369-44AE-87AE-9B37D5B21584Q39402956-201DB118-DEED-4117-A438-BD8B7EF856A4Q39402965-94E53FC9-C752-496A-BD43-589E58B42D3BQ39406817-96DB7933-26D2-4C2C-AAE2-5C5C17717E9BQ39530208-3E017E51-AD24-4BDF-9772-D1E7D7259847
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Raashid Ahmed Luqmani
@ast
Raashid Ahmed Luqmani
@en
Raashid Ahmed Luqmani
@es
Raashid Ahmed Luqmani
@nl
Raashid Ahmed Luqmani
@sl
type
label
Raashid Ahmed Luqmani
@ast
Raashid Ahmed Luqmani
@en
Raashid Ahmed Luqmani
@es
Raashid Ahmed Luqmani
@nl
Raashid Ahmed Luqmani
@sl
prefLabel
Raashid Ahmed Luqmani
@ast
Raashid Ahmed Luqmani
@en
Raashid Ahmed Luqmani
@es
Raashid Ahmed Luqmani
@nl
Raashid Ahmed Luqmani
@sl
P108
P106
P1153
7003619596
P21
P31
P496
0000-0002-4446-5841